Raymond M. Jordt - 01 Jan 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Chief Business Officer
Signature: /s/ Richard I. Eisenstadt as Attorney-in-Fact
Issuer symbol: ALT
Transactions as of: 01 Jan 2024
Net transactions value: -$28,159
Form type: 4
Filing time: 04 Jan 2024, 18:00:32 UTC
Previous filing: 02 Aug 2023
Next filing: 29 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$0	+9,375	+512%	$0.000000	11,207	01 Jan 2024	Direct	F1
transaction	ALT	Common Stock, par value $0.0001	Tax liability	$28,159	-2,503	-22%	$11.25	8,704	01 Jan 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Restricted Stock Units	Options Exercise	$0	-9,375	-25%	$0.000000	28,125	01 Jan 2024	Common Stock, par value $0.0001	9,375		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2	Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3	The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.